Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11946404 | 0.96 | GCK (0.58) | GCK | |
| SCHEMBL14199100 | 0.96 | GCK (0.58) | GCK | |
| SCHEMBL4468993 | 0.93 | GCK (0.57) | GCKHSD17B10 | |
| SCHEMBL4461336 | 0.93 | GCK (0.57) | GCKHSD17B10 | |
| SCHEMBL4461473 | 0.93 | GCK (0.58) | GCK | |
| SCHEMBL4454334 | 0.92 | GCK (0.59) | GCK | |
| SCHEMBL4461614 | 0.89 | GCK (0.56) | GCK | |
| SCHEMBL4465962 | 0.89 | GCK (0.54) | GCK | |
| SCHEMBL11946408 | 0.89 | GCK (0.54) | GCK | |
| SCHEMBL4469025 | 0.89 | GCK (0.54) | GCKHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2077266-B1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | MSD KK (JP) | 2012-07-25 | — | — | EP | claimed |
| EP-2077266-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-08 | — | — | EP | claimed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | claimed |
| EP-2464228-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2676960-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2676961-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2760855-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AS WELL AS THEIR USE IN TREATING TYPE-2 DIABETES | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2571876-B1 | SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9422266-B2 | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2680851-B1 | FUSED BICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9403790-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20100197691-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| WO-2010056708-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
| EP-2178534-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Sharp & Dohme Corp. (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2077266-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009011872-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | GCK 277/4885HSD17B10 519/4885 |
| US-20100197691-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | EPHX1, EPHX2, PTGIS | GCK 1620/4885HSD17B10 166/4885 |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | GCKR, GCK, GPR119 | GCK 2/4885HSD17B10 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.